- Home
- ACXP vs AKTX Comparison
ACXP vs AKTX Comparison
Compare ACXP & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- AKTX
- Stock Information
- Founded
- ACXP 2017
- AKTX N/A
- Country
- ACXP United States
- AKTX United States
- Employees
- ACXP N/A
- AKTX N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- ACXP Health Care
- AKTX Health Care
- Exchange
- ACXP Nasdaq
- AKTX Nasdaq
- Market Cap
- ACXP 31.4M
- AKTX 29.5M
- IPO Year
- ACXP 2021
- AKTX N/A
- Fundamental
- Price
- ACXP $0.87
- AKTX $1.00
- Analyst Decision
- ACXP Strong Buy
- AKTX
- Analyst Count
- ACXP 1
- AKTX 0
- Target Price
- ACXP $12.00
- AKTX N/A
- AVG Volume (30 Days)
- ACXP 297.3K
- AKTX 91.8K
- Earning Date
- ACXP 11-12-2024
- AKTX 02-15-2025
- Dividend Yield
- ACXP N/A
- AKTX N/A
- EPS Growth
- ACXP N/A
- AKTX N/A
- EPS
- ACXP N/A
- AKTX N/A
- Revenue
- ACXP N/A
- AKTX N/A
- Revenue This Year
- ACXP N/A
- AKTX N/A
- Revenue Next Year
- ACXP N/A
- AKTX N/A
- P/E Ratio
- ACXP N/A
- AKTX N/A
- Revenue Growth
- ACXP N/A
- AKTX N/A
- 52 Week Low
- ACXP $0.72
- AKTX $0.90
- 52 Week High
- ACXP $5.28
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- ACXP 31.17
- AKTX 31.38
- Support Level
- ACXP $0.84
- AKTX $0.95
- Resistance Level
- ACXP $0.91
- AKTX $1.13
- Average True Range (ATR)
- ACXP 0.12
- AKTX 0.15
- MACD
- ACXP 0.02
- AKTX 0.02
- Stochastic Oscillator
- ACXP 28.07
- AKTX 15.15
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).